MedPath

METiS Pharmaceuticals Strengthens Leadership Team with Appointment of Mark Herbert as Chief Business Officer

  • METiS Pharmaceuticals has appointed Mark Herbert, former President of Arcturus Therapeutics, as Chief Business Officer to lead global business development and strategic partnerships.

  • The company's AI-driven LNP delivery systems have demonstrated up to 20-fold greater efficacy in liver cancer and lung tumors compared to industry standards.

  • Herbert brings over 20 years of biotech industry experience, having previously generated over $2 billion in partnership value through strategic collaborations with companies like Takeda and CureVac.

METiS Pharmaceuticals, a clinical-stage biotechnology company specializing in AI-driven drug delivery technologies, has appointed Mark Herbert as its Chief Business Officer (CBO), effective January 22, 2025. Herbert will spearhead the company's global business development initiatives and forge strategic partnerships to accelerate the commercialization of its innovative drug delivery platforms.

Strategic Leadership Addition

Herbert joins METiS with over two decades of experience in the biotechnology and pharmaceutical sectors. As the former President of Arcturus Therapeutics, he orchestrated strategic collaborations with industry giants Takeda Pharmaceutical and CureVac, generating partnerships valued at over $2 billion. His extensive portfolio includes executive positions at Varda Space Industries and Scientist.com, along with board memberships across multiple biotech companies.
Dr. Chris Lai, Co-founder and CEO of METiS Pharmaceuticals, emphasized the strategic importance of the appointment: "Mark's proven track record in driving business development and commercialization in the biotech space will be instrumental in strengthening our partnerships and unlocking new growth opportunities as we enter this crucial phase."

Breakthrough Technologies in Drug Delivery

METiS has achieved significant technological breakthroughs in its AI-driven lipid nanoparticle (LNP) delivery systems. The company's innovative platforms have demonstrated remarkable efficacy in targeted nano delivery across multiple organs, including the liver, lungs, spleen, muscles, and central nervous system. Notably, these advanced delivery systems have shown up to 20 times greater efficacy in treating liver cancer and lung tumors compared to current industry standards.
"METiS is at the forefront of using AI to revolutionize drug delivery," Herbert stated. "I'm excited to work with the team to advance our cutting-edge nucleic acid and drug delivery technologies and expand our global partnerships."

Expanding Global Partnerships

Since its founding in 2020, METiS has established itself as a pioneer in programmable nucleic acid therapeutics and next-generation RNA delivery. The company has already secured strategic collaborations with more than 20 leading global pharmaceutical and biotech companies, positioning itself for significant growth in the drug delivery sector.
Dr. Hongmin Chen, Co-founder and CRDO of METiS Pharmaceuticals, noted: "Mark's deep industry knowledge and global perspective will be invaluable as METiS accelerates its growth. His leadership will help enhance our business development efforts and foster partnerships that will bring our transformative drug delivery technologies to patients around the world."
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

HBM Alpha Therapeutics Secures $395M Licensing Deal for Novel CAH Treatment

HBM Alpha Therapeutics has entered a strategic collaboration worth up to $395 million for their anti-CRH antibody therapy HAT001, granting global rights excluding Greater China to their partner.

FDA Grants Second Breakthrough Therapy Designation for Petosemtamab in Head and Neck Cancer

Merus N.V.'s petosemtamab receives FDA Breakthrough Therapy designation for first-line treatment of PD-L1 positive head and neck cancer when combined with pembrolizumab.

Cognito Therapeutics Expands Leadership Team with Four Key Executive Appointments Ahead of Alzheimer's Treatment Launch

Cognito Therapeutics strengthens its executive team with strategic appointments in business, clinical, commercial, and strategy roles as it approaches completion of its pivotal HOPE trial for neurodegenerative disease treatment.

Walden Biosciences Strengthens Board with Appointment of Rare Disease Expert Howard Mayer

Walden Biosciences has appointed Howard Mayer, M.D., former Executive VP of R&D at Ipsen, to its Board of Directors as the company approaches key clinical milestones.

Polyrizon Strengthens Leadership with Appointment of Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Polyrizon Ltd. has appointed Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs, marking a strategic move to bolster its clinical trial efforts for PL-14, set to begin in 2025. With over a decade of experience in the medical device and pharmaceutical industries, Dr. Meir's expertise in regulatory strategy and clinical affairs is expected to significantly contribute to the company's mission of delivering innovative intranasal hydrogels.

Medipost Expands US Presence, Advances CARTISTEM Phase III Trial for Knee Osteoarthritis

Medipost Inc. is expanding its U.S. presence with key executive appointments to drive its regenerative therapy, CARTISTEM, toward a Phase III clinical trial.

Merus' Petosemtamab Shows Promise in HNSCC and NSCLC Trials, Bolstering Investment Potential

Merus' petosemtamab demonstrates a 42.5% overall response rate in Phase 2 trials for second-line or higher head and neck squamous cell carcinoma (HNSCC).

Cyrus Biotechnology Advances AI-Optimized IdeS for Autoimmune Diseases Following Nobel Prize for Co-founder

Cyrus Biotechnology is leveraging AI to refine protein drugs, exemplified by its IdeS variant for autoimmune conditions.

Bioretec Accelerates Development of RemeOs Spinal Interbody Cage Following FDA Breakthrough Designation

Bioretec is expediting the development of its RemeOs™ Spinal Interbody Cage, a device utilizing a magnesium alloy-based absorbable hybrid composite.

MaaT Pharma Advances Microbiome Therapeutics in Oncology

MaaT Pharma, a leading microbiome therapeutics company, is making significant strides in oncology with its innovative treatments. The company's lead product, MaaT013, is currently in phase 3 trials for gastrointestinal acute graft-versus-host Disease (GI-aGvHD), showing promising results. Additionally, MaaT Pharma is exploring the potential of its second candidate, MaaT033, in enhancing overall survival for HSCT and cellular therapy recipients, marking a pivotal moment in microbiome-based cancer treatment.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy